These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27612038)

  • 21. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
    Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
    MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting.
    Kim DS; Lee SH; Kim JS; Lee SC; Kwon MH; Kim YS
    Biochem Biophys Res Commun; 2009 Feb; 379(2):314-8. PubMed ID: 19103171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity.
    Bostrom J; Haber L; Koenig P; Kelley RF; Fuh G
    PLoS One; 2011 Apr; 6(4):e17887. PubMed ID: 21526167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A general approach to antibody thermostabilization.
    McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM
    MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.
    Harding FA; Stickler MM; Razo J; DuBridge RB
    MAbs; 2010; 2(3):256-65. PubMed ID: 20400861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics.
    Van Holsbeeck K; Martins JC; Ballet S
    Bioorg Chem; 2022 Feb; 119():105563. PubMed ID: 34942468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
    Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM
    J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications.
    Kazanecki CC; Kowalski AJ; Ding T; Rittling SR; Denhardt DT
    J Cell Biochem; 2007 Nov; 102(4):925-35. PubMed ID: 17786932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
    Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
    Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and measurement of isoaspartic acid formation in the complementarity determining region of a fully human monoclonal antibody.
    Dick LW; Qiu D; Cheng KC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(30):3841-9. PubMed ID: 19819766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation.
    Chan DTY; Jenkinson L; Haynes SW; Austin M; Diamandakis A; Burschowsky D; Seewooruthun C; Addyman A; Fiedler S; Ryman S; Whitehouse J; Slater LH; Gowans E; Shibata Y; Barnard M; Wilkinson RW; Vaughan TJ; Holt SV; Cerundolo V; Carr MD; Groves MAT
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):16949-16960. PubMed ID: 32616569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.
    Hou S; Li B; Wang L; Qian W; Zhang D; Hong X; Wang H; Guo Y
    J Biochem; 2008 Jul; 144(1):115-20. PubMed ID: 18424812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced antibody affinity to Japanese encephalitis virus E protein by phage display.
    Hong WW; Yen YH; Wu SC
    Biochem Biophys Res Commun; 2007 Apr; 356(1):124-8. PubMed ID: 17350601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy.
    Cao M; De Mel N; Shannon A; Prophet M; Wang C; Xu W; Niu B; Kim J; Albarghouthi M; Liu D; Meinke E; Lin S; Wang X; Wang J
    MAbs; 2019 Apr; 11(3):489-499. PubMed ID: 30786796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
    Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
    J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment.
    Kirley TL; Norman AB
    Hum Vaccin Immunother; 2015; 11(2):458-67. PubMed ID: 25692880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
    Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
    Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.
    Apgar JR; Mader M; Agostinelli R; Benard S; Bialek P; Johnson M; Gao Y; Krebs M; Owens J; Parris K; St Andre M; Svenson K; Morris C; Tchistiakova L
    MAbs; 2016 Oct; 8(7):1302-1318. PubMed ID: 27625211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stress selections on domain antibodies: 'what doesn't kill you makes you stronger'.
    Enever C; Pupecka-Swider M; Sepp A
    Protein Eng Des Sel; 2015 Mar; 28(3):59-66. PubMed ID: 25655396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.